Inca stocks sink as critical drug sales forecasts fall short

• Inca stock fell on Monday as drugmakers’ adjusted earnings for the fourth quarter and sales forecasts for 2025 missed analysts’ expectations.

• The company’s revenue surpassed estimates as the two biggest drugs in the fourth quarter, Jakafi and Opzelura, grew year-over-year.

• Despite the powerful latest quarter of the two drugs, Incyte’s forecast for 2025 sales in 2025 did not reach estimates.

Inset (Inse) Stocks are S&P 500 Analyst estimates failed to reach Monday after forecasts of drugmakers’ fourth quarter adjusted profits and key drug sales in 2025.

Incyte’s fourth quarter sales increased 16% year-on-year to $1.18 billion, with sales of two biggest drugs, Jakafi and Opzelura, up 11% to $773.1 million and 48% respectively. It increased to $161.6 million.

Company adjustments Earnings per share (EPS) It rose from $1.06 last year at $1.43, but was 10 cents below expectations.

Incyte’s outlook for Jakafi and Opzelura sales is also below expectations. The company expects Jakafi’s sales to prevent red blood cell overproduction will lead to Skin Cream Opzelura sales between $2.925 billion and $297.5 billion in 2025. forecast between $630 million and $670 million.

Entering Monday, analysts expected 2025 sales of the two drugs to be sold for around $3.34 billion and $672.2 million, respectively.

Incyte’s shares fell more than 6% on Monday, but have risen about 20% over the past 12 months.

Please read the original article of Investopedia